「Leishmaniasis」の版間の差分

提供: Vaccipedia | Resources for Vaccines, Tropical medicine and Travel medicine
ナビゲーションに移動 検索に移動
 
(同じ利用者による、間の22版が非表示)
1行目: 1行目:
 +
{{TM menu}}
 +
 
==taxonomy==
 
==taxonomy==
 
*phylum ''Sarcomastigophorea'', class ''Zoomastigophorea'', genus ''Leishmania''
 
*phylum ''Sarcomastigophorea'', class ''Zoomastigophorea'', genus ''Leishmania''
5行目: 7行目:
 
==morphology==
 
==morphology==
 
*single flagellum
 
*single flagellum
*kinetoplast
+
*kinetoplast - aggregation of DNA
 
*similar to ''Trypanosoma''
 
*similar to ''Trypanosoma''
  
 
==epidemiology==
 
==epidemiology==
 
*700,000 - 1 mil. new cases per year
 
*700,000 - 1 mil. new cases per year
20,000-30,000 deaths per year
+
*20,000-30,000 deaths per year
  
 
==life cycle==
 
==life cycle==
16行目: 18行目:
 
*promastigote - 10-25 μm
 
*promastigote - 10-25 μm
 
**with flagellum
 
**with flagellum
 +
**transform from amastigote inside sandfly midgut
 +
**proliferate inside midgut
 +
**introduced into human skin directly from sandfly midgut during sandfly bite
 
**phagocytized by macrophage
 
**phagocytized by macrophage
 
*amastigote - 2-4 μm
 
*amastigote - 2-4 μm
 
**transform from promastigote and propagate inside macrophage
 
**transform from promastigote and propagate inside macrophage
 +
**propagetes inside macrophage
 +
**parasitized macrophage finally ruptures and let amasitgote out which eventually by sandfly
 
**transform to promastigote inside sandfly midgut
 
**transform to promastigote inside sandfly midgut
 
*simpler than ''Trypanosoma''
 
*simpler than ''Trypanosoma''
24行目: 31行目:
 
*host: human, dog, rodent
 
*host: human, dog, rodent
  
==clinical manifestation==
+
===sandfly===
===visceral leishmania===
+
*''Phlebotomus'' spp.
 +
**Eurasian
 +
*''Lutzomya'' spp.
 +
**Latin America
 +
*Feed during night
 +
*Bitten site by sandfly produces asymptomatic papule, eventually enlarges to an ulcerated nodule and will be spontaneously healed
 +
 
 +
==visceral leishmania==
 
*most serious
 
*most serious
 
*same as Kala-azar
 
*same as Kala-azar
 
**Latin "black fever"
 
**Latin "black fever"
*fever
+
*incubation 3 weeks to > 2 years
*weight loss
+
**reason of diversity of incubation unknown
*hepatosplenomegaly
+
*symptoms
*anemia
+
**fever -generally low grade
*50,000-90,000 new cases per year
+
**weight loss
 +
**hepatosplenomegaly - extremely substantial
 +
***completely subsides rapidly by treatment
 +
**cough, diarrhea
 +
**anemia, leukopenia, thrombocytopenia
 +
*many patients are asymptomatic and cured spontaneously
 +
**cell-mediated immunity
 +
**mass treatment of asymptomatic patients is very problematic because of lacking of easily taken oral short course drug
 +
*50,000-90,000 new cases reported per year 2004-2008
 +
*202,200-389,100 new cases estimated per year 2004-2008 - underreporting
 
**mainly children affected
 
**mainly children affected
**India, Ethiopia, South Sudan, Brazil
+
**India, Ethiopia, South Sudan, Uganda, Brazil
 +
***South Asia- decreasing trend towards elimination
 +
***South Asia- epidemic wave pattern every 15 years
 +
***East Africa- no decreasing trends
 +
***East Africa-
 +
***Latin America-
 
*''L. donovani''
 
*''L. donovani''
 
**India, Africa
 
**India, Africa
41行目: 69行目:
 
*''L. infantum'' (formerly ''L. chagasi'' was thought separated species)
 
*''L. infantum'' (formerly ''L. chagasi'' was thought separated species)
 
**Mediterranean, China, South America
 
**Mediterranean, China, South America
**dog is reservoir
+
**dog, cattle is reservoir
 +
 
 +
===diagnosis of visceral leishmania===
 +
*suspect for >2 weeks fever+splenomegaly with geographical relation
 +
*detection of amastigote in smear of bone marrow aspiration, lymph node or spleen aspiration
 +
**sensitivity 93-99% in spleen aspirate, 53-86% in bone marrow aspirate, 53-65% in lymph node aspirate
 +
***0.1% of life-threatening hemorrhage by spleen aspiration
 +
*culture in NNN media
 +
*immunochromatographical detection of rk39 antigen
 +
**dip stick form
 +
**97-100% sensitivity in Asia, low in Africa
 +
***reason unkown, possibly the difference of subspecies
 +
**cannot distinguish between active or relapse
 +
**unkown sensitivity in HIV co-infection
 +
*in areas of high HIV prevelence all leischmeniasis patients should be screened for HIV
 +
*PCR
 +
*importance of accurate diagnosis
 +
**clinical features of VL resemble
 +
*DDx
 +
**chronic malaria
 +
**schistosomiasis
 +
**typhoid
 +
**tuberculosis - splenomegaly is rare unless miliary TB
 +
**hematological malignancy
 +
*can be verically transmitted - rare
 +
*Treatment
 +
**to reduce parasite burden
 +
**to improve complication
 +
**to help to induce cell-mediated immunity
 +
*Tx in India
 +
**liposomal AMPH-B
 +
***+miltefosine
 +
***+paromomycin
 +
***+
 +
**AMPH-B - adherence is diffucult
 +
**miltefosine - adherence is diffucult; now is only for combination with liposomal AMPH-B
 +
**drug interactions
 +
*Tx in East Africa
 +
**
 +
*Tx for ''L. infantum'' in Latin America
 +
**
 +
 
  
====post kala-azar dermal leishmanisis (PKDL)====
+
===post kala-azar dermal leishmanisis (PKDL)===
 
*skin manifestation after completion of Tx of visceral leishmaniasis
 
*skin manifestation after completion of Tx of visceral leishmaniasis
 
**macular type, papular type, nodular type
 
**macular type, papular type, nodular type
 +
**possibly 5-10% of VL patients
 +
**incidence 4.8/1000 in India
 
*''Leishmania'' may be detected from skin specimen in some cases
 
*''Leishmania'' may be detected from skin specimen in some cases
**possible reservoir
+
**skin is contagious
 +
**reservoir
 +
*diagnosis
 +
**history of VL
 +
**rK39
 +
*treatment
 +
**no good evidence
 +
**miltefosine for 12 weeks
  
 
+
==cutaneous leishmania==
===cutaneous leishmania===
 
 
*most common
 
*most common
*same as Oriental sore
+
*same as Oriental sore, Chiclero ulcer (in Latin America)
 
*papule, nodule → ulcer → scar
 
*papule, nodule → ulcer → scar
 +
*basically self-limited
 
*rarely diffuce or disseminated
 
*rarely diffuce or disseminated
*600,000-1 mil. new cases per year
+
*700,000-1.2 mil. new cases per year
*Afghanistan, Algeria, Brazil, Colombia, Iran, Syria
+
*90% of cases are from 7 countries
 +
**Afghanistan, Pakistan, Iran, Syria, Saudi Arabia, Algeria, Brazil, Colombia
 +
***completely different from VL countries but Brazil
 
**imported in Texas, US in 2015
 
**imported in Texas, US in 2015
 +
**cutaneous leishmaniasis by ''L. donovani'' is reported in Sri Lanka
 +
**tends to increase in conflict area, mass displacement, military deployment
 +
***especially in Syria since its civil war
 
*''L. tropica'', ''L. mexicana'', ''L. amazonensis'' and other species >20
 
*''L. tropica'', ''L. mexicana'', ''L. amazonensis'' and other species >20
 +
*"old world" Africa and South Asia
 +
*"new world" Latin America
 +
*''Rhombomys opimus'' (great gerbil) is primary reservoir
 +
 +
===transmission===
 +
*anthroponotic (''L. tropica'') or zoonotic (other species)
 +
*skin contact with active lesion innocuous
 +
*risk factors
 +
**poor quality housing
 +
**male
 +
**younger age <15 y/o
 +
**proximity to forest
 +
**domestic dog ownership
 +
**sleeping in temporary shelters
 +
 +
===clinical features===
 +
*no life threatening
 +
*significant cosmetic morbidity
 +
**stigmatization
 +
*old world
 +
**dryer, warty, scaly
 +
*new world
 +
**wet, ulcerative
 +
**lymphadenopathy
 +
 +
====diffuse cutaneous leishmaniasis====
 +
*rare form of CL
 +
*nodular, papular
 +
 +
====disseminated CL====
 +
*rare form of CL
 +
*>10 mixed type skin lesions
 +
*in immunocompromised host
 +
 +
====leishmania recidivans====
 +
*by ''L. tropica''
 +
*new lesions encircling years-old scar
  
===mucocutaneous leishmania===
+
===diagnosis of cutaneous leishmaniasis===
 +
*smear of fine needle aspirate or biopsy of skin lesion
 +
**specimen from ulcer margin is the highest yield
 +
**fine needle aspiration cytology is generally better
 +
*serological test is of no use; low sensitivity and variable specificity
 +
*NAAT is available
 +
 
 +
====DDx of CL====
 +
**staphylococcal infection
 +
**streptococcal infection
 +
**mycobacterial ulcer
 +
**fungal ulcer
 +
**cancer
 +
**sarcoidosis
 +
**tropical ulcer -
 +
 
 +
==mucocutaneous leishmania==
 +
*only in new world CL
 +
**Bolivia, Brazil, Peru
 +
*same as Espundia, white leprosy
 +
*lyphatic or hematogenous dissemination to mucosa in mouth and/or upper respiratory tract, resulted in destruction and deformity of nose, palate, pharynx
 +
*''L. braziliensis'', ''L. panamensis''
 +
*progressive ever without treatment
 +
*secondary bacterial infection
 +
*worsening nasal congestion, epistaxis or discharge common
 +
*permanent disfigurement of face
 +
**cleft palate, nasal septum destruction, "Tapir" nose
 +
 
 +
===diagnosis of mucocutaneous leishmaniasis===
 +
*leishmania is scarce in mucosal lesion
 +
**strong local immune response
 +
*serology or molecular
  
 
==emerging novel leishmaniasis==
 
==emerging novel leishmaniasis==
 
*in Thailand
 
*in Thailand
 
*''L. siamensis'', ''L. martiniquensis''
 
*''L. siamensis'', ''L. martiniquensis''
 +
 +
==treatment==
 +
*majority spontaneously healed in 2-15months
 +
*distinguish simple or complex
 +
**complex -
 +
*new world needs more to identify species to anticipate of progression to mucocutaneous CL
 +
 +
 +
*pentavalent antimonial
 +
**meglumine antimoniate
 +
**sodium stibogluconate
 +
*amphotericin B
 +
**liposomal amphotericin B
 +
*paromomycin
 +
*pentamidine
 +
*miltefosine
 +
 +
 +
*cryotherapy
 +
**liquid nitrogen
 +
*thermotherapy
 +
**40-42℃ for 3min.
 +
***50℃ for 30 sec.
 +
**make second degree burn
 +
 +
 +
*topical application
 +
 +
==vaccine==
 +
*no human vaccine
 +
*canine vaccine has been rolled out
 +
*"leishmanization" in Uzbeskistan
 +
**intradermal inoculation of live wild strain of ''L. major''
 +
 +
==control==
 +
*case detection and treatment for anthroponotic leishmaniasis
 +
*vector control for sandfly-borne leishmaniasis
 +
*destruction of burrows of great gerbil
 +
 +
==GHIT Fund==
 +
Global Health Innovative Technology Fund
 +
*supported by Japanese Government

2022年10月15日 (土) 21:41時点における最新版

Navigation Menu Vac logo.png
General issues of Vaccine
Cold chain
Correlates of Protection
Vaccines for Asplenia
Vaccines for Pregnant women
Vaccines for Immunocompromised hosts
Vaccine hesitancy
Additional materials of vaccine
General issues of Tropical med.
Definition of Tropical Medicine
Matrices of tropical infection
General issues of Helminths
Neglected Tropical Diseases
Sexually-transmitted infections
Non-Communicable Diseases
Maternal health and contraception
Child health
Malnutrition and Micronutrient
Eosinophilia
Fever in the tropics
Diarrhea in the tropics
Anemia in the tropics
Dermatology in the tropics
Ophthalmology in the tropics
Neurology in the tropics
Mental health in the tropics
Surgery in the tropics
Humanitarian emergency
Epidemiology in outbreak
Antimicrobial resistance
Pathology of infectious diseases
General issues of Travel med.
Epidemiology of Travel health
Last minute traveler
Time zone issue
High altitude medicine
Diving medicine
Pregnancy and travel
Children and travel
Elderly and travel
Immunology
Principle of human immune system
Innate immunity
Cellular immunity
Humoral immunity
Neutralizing antibody and its assay
Antigenic Cartography
Additional materials of immunology
Epi & Stats
Basics & Definition
Epidemiology
Odds in statistics and Odds in a horse race
Collider bias
Data distribution
Statistical test
Regression model
Multivariate analysis
Marginal effects
Prediction and decision
Table-related commands in STATA
Missing data and imputation
Virus
HIV
HIV-TB co-infection
HIV-STI interaction
Viral Hemorrhagic Fever
Ebola
Crimean-Congo hemorrhagic fever
SFTS
Rabies
Polio
Dengue
Yellow fever
Chikungunya
Zika
Japanese encephalitis
Tick-borne encephalitis
Viral hepatitis
Measles
Smallpox and Monkeypox
Respiratory Syncytial virus
COVID-19
Bivalent BA.1/BA.4-5 mRNA vaccines
Monovalent XBB-1.5 mRNA vaccine
Private archives of the initial phase of the pandemic
Private archives of lecture materials of COVID vaccine as of March 2021
厚生労働省が発出する保健行政関連の文書の読み解き方
Bacteria
Bacteriological tests
Tuberculosis
Tuberculosis in Children
HIV-TB co-infection
Leprosy
Dermatological mycobacterium infecions
Syphilis and Yaws
Plague
Pneumococcus
Meningococcus
Typhoid
Salmonellosis
Melioidosis
Leptospirosis
Brucellosis
Bartonellosis
Lyme disease and Relapsing fever
Tularaemia
Tetanus
Diphtheria
Anthrax
Coxiellosis
Rickettsia
Rickettsiosis
Scrub typhus
Spotted fevers
Epidemic typhus
Murine typhus
Protozoa
Overview of protozoa
Overview of medicine for protozoa
Malaria
Chagas disease
African trypanosomiasis
Leishmaniasis
Trichomoniasis
Toxoplasmosis
Amoebiasis
Giardiasis
Cryptosporidiosis
Cyclosporiasis
Isosporiasis
Pentatrichomoniasis
Microsporidiasis
Babesiosis
Fungi
General issues of fungi
Coccidioidomycosis
Paracoccidioidomycosis
Histoplasmosis
Talaromycosis
Blastomycosis
Sporotrichosis
Nematode (roundworm)
Nematode principles
Lympatic filariasis
Onchocerciasis
Loiasis
Microscopic differentiation of microfilariae
Strongyloidiasis
Ascariasis
Ancylostomiasis (hookworm)
Trichuriasis (whipworm)
Enterobiasis (pinworm)
Angiostrongyliasis (rat lungworm)
Dracunculiasis (Guinea worm)
Anisakiasis
Trichinellosis (Trichinosis)
Gnathostomiasis
Spirurinasis
Soil-transmitted helminths
Trematode (fluke, distoma)
General issues of Helminths
Trematode principles
Schistosomiasis
Clonorchiasis
Fascioliasis
Paragonimiasis
Metagonimiasis
Cestode (tapeworm)
General issues of Helminths
Cestode principles
Diphyllobothriasis
Sparganosis
Taeniasis
Echinococcosis
Medical Zoology
Zoonosis
Insectology
Mosquitology
Acarology
Batology
Snake toxicology
Scorpion and spider toxicology
Marine toxicology

Chevron-up-blue.png

taxonomy

  • phylum Sarcomastigophorea, class Zoomastigophorea, genus Leishmania
    • Plasmodium belongs to phylum Apicomplexa

morphology

  • single flagellum
  • kinetoplast - aggregation of DNA
  • similar to Trypanosoma

epidemiology

  • 700,000 - 1 mil. new cases per year
  • 20,000-30,000 deaths per year

life cycle

  • parasitize in human macrophage
  • promastigote - 10-25 μm
    • with flagellum
    • transform from amastigote inside sandfly midgut
    • proliferate inside midgut
    • introduced into human skin directly from sandfly midgut during sandfly bite
    • phagocytized by macrophage
  • amastigote - 2-4 μm
    • transform from promastigote and propagate inside macrophage
    • propagetes inside macrophage
    • parasitized macrophage finally ruptures and let amasitgote out which eventually by sandfly
    • transform to promastigote inside sandfly midgut
  • simpler than Trypanosoma
  • vector: sandfly
  • host: human, dog, rodent

sandfly

  • Phlebotomus spp.
    • Eurasian
  • Lutzomya spp.
    • Latin America
  • Feed during night
  • Bitten site by sandfly produces asymptomatic papule, eventually enlarges to an ulcerated nodule and will be spontaneously healed

visceral leishmania

  • most serious
  • same as Kala-azar
    • Latin "black fever"
  • incubation 3 weeks to > 2 years
    • reason of diversity of incubation unknown
  • symptoms
    • fever -generally low grade
    • weight loss
    • hepatosplenomegaly - extremely substantial
      • completely subsides rapidly by treatment
    • cough, diarrhea
    • anemia, leukopenia, thrombocytopenia
  • many patients are asymptomatic and cured spontaneously
    • cell-mediated immunity
    • mass treatment of asymptomatic patients is very problematic because of lacking of easily taken oral short course drug
  • 50,000-90,000 new cases reported per year 2004-2008
  • 202,200-389,100 new cases estimated per year 2004-2008 - underreporting
    • mainly children affected
    • India, Ethiopia, South Sudan, Uganda, Brazil
      • South Asia- decreasing trend towards elimination
      • South Asia- epidemic wave pattern every 15 years
      • East Africa- no decreasing trends
      • East Africa-
      • Latin America-
  • L. donovani
    • India, Africa
    • anthroponotic = maintained in human-to-human infection
  • L. infantum (formerly L. chagasi was thought separated species)
    • Mediterranean, China, South America
    • dog, cattle is reservoir

diagnosis of visceral leishmania

  • suspect for >2 weeks fever+splenomegaly with geographical relation
  • detection of amastigote in smear of bone marrow aspiration, lymph node or spleen aspiration
    • sensitivity 93-99% in spleen aspirate, 53-86% in bone marrow aspirate, 53-65% in lymph node aspirate
      • 0.1% of life-threatening hemorrhage by spleen aspiration
  • culture in NNN media
  • immunochromatographical detection of rk39 antigen
    • dip stick form
    • 97-100% sensitivity in Asia, low in Africa
      • reason unkown, possibly the difference of subspecies
    • cannot distinguish between active or relapse
    • unkown sensitivity in HIV co-infection
  • in areas of high HIV prevelence all leischmeniasis patients should be screened for HIV
  • PCR
  • importance of accurate diagnosis
    • clinical features of VL resemble
  • DDx
    • chronic malaria
    • schistosomiasis
    • typhoid
    • tuberculosis - splenomegaly is rare unless miliary TB
    • hematological malignancy
  • can be verically transmitted - rare
  • Treatment
    • to reduce parasite burden
    • to improve complication
    • to help to induce cell-mediated immunity
  • Tx in India
    • liposomal AMPH-B
      • +miltefosine
      • +paromomycin
      • +
    • AMPH-B - adherence is diffucult
    • miltefosine - adherence is diffucult; now is only for combination with liposomal AMPH-B
    • drug interactions
  • Tx in East Africa
  • Tx for L. infantum in Latin America


post kala-azar dermal leishmanisis (PKDL)

  • skin manifestation after completion of Tx of visceral leishmaniasis
    • macular type, papular type, nodular type
    • possibly 5-10% of VL patients
    • incidence 4.8/1000 in India
  • Leishmania may be detected from skin specimen in some cases
    • skin is contagious
    • reservoir
  • diagnosis
    • history of VL
    • rK39
  • treatment
    • no good evidence
    • miltefosine for 12 weeks

cutaneous leishmania

  • most common
  • same as Oriental sore, Chiclero ulcer (in Latin America)
  • papule, nodule → ulcer → scar
  • basically self-limited
  • rarely diffuce or disseminated
  • 700,000-1.2 mil. new cases per year
  • 90% of cases are from 7 countries
    • Afghanistan, Pakistan, Iran, Syria, Saudi Arabia, Algeria, Brazil, Colombia
      • completely different from VL countries but Brazil
    • imported in Texas, US in 2015
    • cutaneous leishmaniasis by L. donovani is reported in Sri Lanka
    • tends to increase in conflict area, mass displacement, military deployment
      • especially in Syria since its civil war
  • L. tropica, L. mexicana, L. amazonensis and other species >20
  • "old world" Africa and South Asia
  • "new world" Latin America
  • Rhombomys opimus (great gerbil) is primary reservoir

transmission

  • anthroponotic (L. tropica) or zoonotic (other species)
  • skin contact with active lesion innocuous
  • risk factors
    • poor quality housing
    • male
    • younger age <15 y/o
    • proximity to forest
    • domestic dog ownership
    • sleeping in temporary shelters

clinical features

  • no life threatening
  • significant cosmetic morbidity
    • stigmatization
  • old world
    • dryer, warty, scaly
  • new world
    • wet, ulcerative
    • lymphadenopathy

diffuse cutaneous leishmaniasis

  • rare form of CL
  • nodular, papular

disseminated CL

  • rare form of CL
  • >10 mixed type skin lesions
  • in immunocompromised host

leishmania recidivans

  • by L. tropica
  • new lesions encircling years-old scar

diagnosis of cutaneous leishmaniasis

  • smear of fine needle aspirate or biopsy of skin lesion
    • specimen from ulcer margin is the highest yield
    • fine needle aspiration cytology is generally better
  • serological test is of no use; low sensitivity and variable specificity
  • NAAT is available

DDx of CL

    • staphylococcal infection
    • streptococcal infection
    • mycobacterial ulcer
    • fungal ulcer
    • cancer
    • sarcoidosis
    • tropical ulcer -

mucocutaneous leishmania

  • only in new world CL
    • Bolivia, Brazil, Peru
  • same as Espundia, white leprosy
  • lyphatic or hematogenous dissemination to mucosa in mouth and/or upper respiratory tract, resulted in destruction and deformity of nose, palate, pharynx
  • L. braziliensis, L. panamensis
  • progressive ever without treatment
  • secondary bacterial infection
  • worsening nasal congestion, epistaxis or discharge common
  • permanent disfigurement of face
    • cleft palate, nasal septum destruction, "Tapir" nose

diagnosis of mucocutaneous leishmaniasis

  • leishmania is scarce in mucosal lesion
    • strong local immune response
  • serology or molecular

emerging novel leishmaniasis

  • in Thailand
  • L. siamensis, L. martiniquensis

treatment

  • majority spontaneously healed in 2-15months
  • distinguish simple or complex
    • complex -
  • new world needs more to identify species to anticipate of progression to mucocutaneous CL


  • pentavalent antimonial
    • meglumine antimoniate
    • sodium stibogluconate
  • amphotericin B
    • liposomal amphotericin B
  • paromomycin
  • pentamidine
  • miltefosine


  • cryotherapy
    • liquid nitrogen
  • thermotherapy
    • 40-42℃ for 3min.
      • 50℃ for 30 sec.
    • make second degree burn


  • topical application

vaccine

  • no human vaccine
  • canine vaccine has been rolled out
  • "leishmanization" in Uzbeskistan
    • intradermal inoculation of live wild strain of L. major

control

  • case detection and treatment for anthroponotic leishmaniasis
  • vector control for sandfly-borne leishmaniasis
  • destruction of burrows of great gerbil

GHIT Fund

Global Health Innovative Technology Fund

  • supported by Japanese Government